Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study

The Lancet Global Health

Volumn 2, Issue 7, 2014, Pages e406-e414

  Jit, Mark ^a,b   Brisson, Marc ^c,d,e   Portnoy, Allison ^f   Hutubessy, Raymond ^g  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LAVAL UNIVERSITY   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITÉ LAVAL   (Canada)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; INTERNATIONAL COOPERATION; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VALIDATION STUDY;

WART VIRUS VACCINE;

CHILD; COST-BENEFIT ANALYSIS; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION PROGRAMS; INTERNATIONALITY; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84908380305     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70237-2     Document Type: Article

References (30)

1. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84:118-131. No authors listed.
2. Dorleans F, Giambi C, Dematte L, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15:19730.
3. Jit M, Levin C, Brison M, et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med 2013, 11:23.
4. Historical analysis of the comprehensive multi-year plans in GAVI-eligible countries (2004-2015), 2012 Bill & Melinda Gates Foundation, WHOWHO, (accessed Dec 1, 2013). http://www.who.int/immunization_financing/analysis/Historical_cMYP_Analysis_2012.pdf.
5. GAVI funds vaccines to protect girls against cervical cancer GAVI Alliance, (accessed Feb 10, 2013). http://www.gavialliance.org/library/news/press-releases/2013/gavi-funds-vaccines-to-protect-girls-against-cervical-cancer/.
6. Andrus JK, Toscano CM, Lewis M, et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 2007, 122:811-816.
7. GAVI Alliance pilot prioritisation mechanism, 2010 GAVI Alliance, (accessed May 22, 2014). http://www.webcitation.org/6PlgCyORa.
8. Fesenfeld M, Hutubessy R, Jit M Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine 2013, 31:3786-3804.
9. Brisson M, Van de Velde NV, Boily MC Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
10. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26:K76-K86.
11. Bonanni P, Boccalini S, Bechini A Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009, 27:A46-A53.
12. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093.
13. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2010 revision (accessed May 1, 2013).
14. Mathers CD, Lopez AD, Murray CJL The burden of disease and mortality by condition: data, methods and results for 2001. Global Burden of Disease and Risk Factors 2006, World Bank, Washington, DC. A.D. Lopez, C.D. Mathers, M. Ezzati (Eds.).
15. Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95:S43-103.
16. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C Screening, prevention and treatment of cervical cancer-a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27:6060-6079.
17. WHO. Global Health Observatory Database, 2008. (accessed Feb 22, 2011).
18. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
19. GLOBOCAN 2008. Cancer fact sheet. Cervical cancer incidence and mortality worldwide in 2008 International Agency for Research on Cancer, (accessed June 4, 2014). http://web.archive.org/web/20130831045805/http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
20. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Cancer fact sheets. Cervix uteri International Agency for Research on Cancer, (accessed March 27, 2014). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
21. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organization, Geneva. T. Tan-Torres Edejer, R. Baltussen, T. Adam (Eds.).
22. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30:F139-F148.
23. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009, 27:127-147.
24. Seto K, Marra F, Raymakers A, Marra CA The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012, 72:715-743.
25. Koleva D, De Compadri P, Padula A, Garattini L Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med 2011, 6:163-174.
26. Van Kriekinge G, Castellsague X, Cibula D, Demarteau N Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine 2014, 32:733-739.
27. Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Vaccine 2013, 31:F60-F72.
28. Kim JJ, Sharma M, O'Shea M, et al. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). Vaccine 2013, 31:G65-G77.
29. Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 2013, 31:H71-H79.
30. Broutet N Comprehensive cervical cancer control: strategies and guidelines. Epidemiologic studies in cancer prevention and screening 2013, 209-221. Springer.